contravir pharmaceuticals adds carol l brosgart md to scientific advisory board contravir pharmaceuticals adds carol l brosgart md to scientific advisory board jan    et from contravir pharmaceuticals inc edison nj jan   prnewswire  contravir pharmaceuticals inc otcbb ctrv a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies announced today the addition of carol l brosgart md to the companys scientific advisory board sab to support the development of its targeted antiviral therapies including cmx a highly potent analog of the antiviral drug tenofovir which contravir plans to develop for hbv  dr brosgart has a strong background and expertise in viral infectious diseases particularly hepatology james sapirstein chief executive officer of contravir commented i am excited to work with dr brosgart again after working together at gilead on the clinical development of tenofovir as well as on the board of tobira pharmaceuticals  there is no one i trust more than her to provide advice and guidance particularly for our hbv program given her experience in this space  she joins our sab chairman dr nate katz the foremost authority on postherpetic neuralgia phn pain and together their unparalleled expertise will be extremely valuable to contravir as we advance clinical development for fv and cmx carol brosgart md serves as special adviser on health care for fipra international and as a consultant to biotechnology companies she is a clinical professor of medicine in the divisions of global health sciences biostatistics and epidemiology in the department of medicine at the university of california san francisco ucsf from  through  she served as the senior advisor on science and policy to the division of viral hepatitis at the centers for disease control and to the viral hepatitis action coalition at the cdc foundation she has held a number of senior management positions in the medical and biotechnology community including chief medical officer and senior vice president at alios biopharma and senior vice president and chief medical officer childrens hospital  research center in oakland california from  to 9 dr brosgart held a number of senior management positions at gilead sciences inc including vice president public health and policy vice president medical affairs and vice president clinical research during her tenure leading clinical research at gilead viread® and hepsera® were approved by the fda and regulatory agencies worldwide dr brosgart was a practicing physician before joining gilead and was the founding medical director of the east bay aids center at alta bates medical center in berkeley california from  through  and the medical director of central health center alameda county health care services agency from  she is active professionally in the infectious diseases society of america the hiv medical association the american association for the study of liver disease and the european association for the study of liver disease she serves on the executive committee of the forum for collaborative hiv research at the university of california berkeley school of public health and on the board of directors of the pangaea global aids foundation and the national viral hepatitis round table she recently completed six years on the board of the san francisco aids foundation dr brosgart has published extensively in the areas of hivaids hbv hcv and cmv she received her bs in community medicine from the university of california berkeley ucb and her md from ucsf about contravir pharmaceuticals contravir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in midtolate stage clinical development contravirs lead candidate fv is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster or shingles which is an infection caused by the reactivation of varicella zoster virus vzv  in addition to direct antiviral activity fv has demonstrated the potential to reduce the incidence of debilitating shinglesassociated pain known as postherpetic neuralgia phn in a phase  clinical study  contravir is also developing cmx a highly potent analog of the successful antiviral drug tenofovir df viread®  cmx is active against hbv and more than fold more potent in vitro versus tenofovir against all major hiv subtypes resistant to current therapies  cmxs novel structure results in decreased circulating levels of tenofovir lowering systemic exposure and thereby reducing the potential for renal side effects  contravir intends to develop cmx for hbv and hiv in phase  clinical studies  forward looking statements certain statements in this press release are forwardlooking within the meaning of the private securities litigation reform act of  these statements may be identified by the use of forwardlooking words such as anticipate believe forecast estimated and intend among others these forwardlooking statements are based on contravirs current expectations and actual results could differ materially there are a number of factors that could cause actual events to differ materially from those indicated by such forwardlooking statements these factors include but are not limited to substantial competition our ability to continue as a going concern our need for additional financing uncertainties of patent protection and litigation uncertainties with respect to lengthy and expensive clinical trials that results of earlier studies and trials may not be predictive of future trial results uncertainties of government or third party payer reimbursement limited sales and marketing efforts and dependence upon third parties and risks related to failure to obtain fda clearances or approvals and noncompliance with fda regulations as with any drug candidates under development there are significant risks in the development regulatory approval and commercialization of new products there are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful contravir does not undertake an obligation to update or revise any forwardlooking statement investors should read the risk factors set forth in contravirs form k for the year ended december   and other periodic reports filed with the securities and exchange commission for further information please contact tiberend strategic advisors inc joshua drumm phd investors jdrummtiberendcom   claire sojda media csojdatiberendcom   source contravir pharmaceuticals inc view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more feb    et preview contravir to present at two upcoming investor conferences jan    et preview contravir to present at noble financial conference my news release contains wide tables view fullscreen read more feb    et contravir to highlight clinical data from ongoing phase a study more news releases in health care  hospitals medical pharmaceuticals pharmaceuticals personnel announcements looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search carol l brosgart – contravir pharmaceuticals press enter to begin your search about company overview leadership partnering pipeline drug candidates txl™ crv valnivudine™ disease areas chronic hepatitis b shingles clinical trials scientific literature intellectual property newsroom press releases newsroom all media placements videos investors overview news releases events  presentations stock information stock quote  chart historical price lookup investment calculator analyst coverage financials  filings sec filings fundamentals annual reports  proxy statements corporate governance documents  charters leadership board of directors comittee composition investor resources investor faqs email alerts contact ir rss feeds search contact contact us careers carol l brosgart md chair scientific advisory board carol brosgart md serves as special adviser on health care for fipra international and as a consultant to biotechnology companies she is a clinical professor of medicine in the divisions of global health sciences biostatistics and epidemiology in the department of medicine at the university of california san francisco ucsf from  through  she served as the senior advisor on science and policy to the division of viral hepatitis at the centers for disease control and to the viral hepatitis action coalition at the cdc foundation she has held a number of senior management positions in the medical and biotechnology community including chief medical officer and senior vice president at alios biopharma and senior vice president and chief medical officer children’s hospital  research center in oakland california from  to 9 dr brosgart held a number of senior management positions at gilead sciences inc including vice president public health and policy vice president medical affairs and vice president clinical research during her tenure leading clinical research at gilead viread® and hepsera® were approved by the fda and regulatory agencies worldwide dr brosgart was a practicing physician before joining gilead and was the founding medical director of the east bay aids center at alta bates medical center in berkeley california from  through  and the medical director of central health center alameda county health care services agency from  she is active professionally in the infectious diseases society of america the hiv medical association the american association for the study of liver disease and the european association for the study of liver disease she serves on the executive committee of the forum for collaborative hiv research at the university of california berkeley school of public health and on the board of directors of the pangaea global aids foundation and the national viral hepatitis round table she recently completed six years on the board of the san francisco aids foundation dr brosgart has published extensively in the areas of hivaids hbv hcv and cmv she received her bs in community medicine from the university of california berkeley ucb and her md from ucsf get important news and updates by email subscribe   contravir pharmaceuticals  disclaimer  terms of use galmed pharmaceuticals announces the election of dr carol l brosgart as a new member of the board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp  dow  nasdaq listentop economists debate state of labor marketyahoo finances nicole sinclair moderates a panel of leading economists at the state of the labor market summitgalmed pharmaceuticals announces the election of dr carol l brosgart as a new member of the board of directorspr newswirejune  reblogsharetweetsharetel aviv israel june   prnewswire  galmed pharmaceuticals ltd glmd galmed or the company a clinicalstage biopharmaceutical company focused on the development of a oncedaily oral therapy for the treatment of nonalcoholic steatohepatitis or nash and other liver diseases announced today that on june   the company held an annual general meeting of shareholders the meeting at which the companys shareholders voted to elect dr carol l brosgart as a new class i director to serve as a member of the board of directors until the close of the annual general meeting to be held in dr brosgart brings a vast array of clinical policy and corporate experience to galmed having held senior management positions with several leading pharmaceutical and life sciences companies dr brosgart as vice president clinical research at gilead sciences oversaw the nda eu and global approvals and launches of viread™ for hiv and hepsera™ for hepatitis b recently she served for eight years as a member of the board of directors of tobira therapeutics until it was acquired by allergan in november  she is also active in the public policy arena for aasld and idsahivma dr brosgart is a member of the executive committee of the forum for collaborative research fcr at the university of california berkeley and has served on both the steering committee of the fcrs liver forum which is a leader in the field of collaborative research focused on nash and the fcrs hbv forum focused on cure research for hepatitis b she has published widely in the field of chronic viral infections and liver disease and serves as a clinical professor of medicine biostatistics and epidemiology at the university of california san francisco ucsfallen baharaff galmeds president and chief executive officer stated dr brosgart has extensive clinical and drug development experience with direct relevance to both our clinical studies in nash the arrest study and hiv associated nafld and lipodystrophy the arrive study we believe her experience in launching successful new drugs and navigating commercial launches and corporate transactions will prove invaluable to galmed as we continue our drug development in chronic liver diseasedr brosgart stated i am pleased to join the board of directors of galmed a leading company in clinical research in nash and fibrosis nash a chronic progressive liver disease in the spectrum of nonalcoholic fatty liver disease has rapidly become a leading cause for endstage liver disease hepatocellular carcinoma and liver transplantation both in the united states and globally nash is a complex disease that will likely require therapy that addresses the underlying metabolic abnormalities in addition to inflammation and fibrosisfor the full results of the meeting please refer to the companys form k filed with the securities and exchange commission on june  about aramchol™ and nonalcoholic steatohepatitis nasharamchol™ arachidyl amido cholanoic acid is a novel fatty acid bile acid conjugate inducing beneficial modulation of intrahepatic lipid metabolism aramchol™s ability to modulate hepatic lipid metabolism was discovered and validated in animal models demonstrating down regulation of the three key pathologies of nash steatosis inflammation and fibrosis the effect of aramchol™ on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells aramchol™ has been granted by the fda fast track designation status for the treatment of nashnash is an emerging world crisis impacting  to  of the us population and  to  globally it is the fastest growing cause of liver cancer and liver transplant in the us due to the rise in obesity nash is the progressive form of nonalcoholic fatty liver disease that can lead to cardiovascular disease cirrhosis and liverrelated mortalityabout galmed pharmaceuticals ltdgalmed is a clinicalstage biopharmaceutical company focused on the development of aramchol™ a first in class novel oncedaily oral therapy for the treatment of nash for variable populations as well as other liver associated disorders galmed is currently conducting the arrest study a multicenter randomized double blind placebocontrolled phase iib clinical study designed to evaluate the efficacy and safety of aramchol™ in subjects with nash who are overweight or obese and who are prediabetic or typeiidiabetic galmed also sponsors the arrive study a proofofconcept phase iia clinical trial designed to evaluate the safety and efficacy of aramchol in up to  patients with hivassociated nafld and lipodystrophy the arrive study is an investigatorinitiated trial conducted at the university of california san diego by professor rohit loomba more information about the arrest study and the arrive study may be found on clinicaltrialsgov identifiers nct9 and nct9 respectivelyread moreforwardlooking statementsthis press release may include forwardlooking statements forwardlooking statements may include but are not limited to statements relating to galmeds objectives plans and strategies as well as statements other than historical facts that address activities events or developments that galmed intends expects projects believes or anticipates will or may occur in the future these statements are often characterized by terminology such as believes hopes may anticipates should intends plans will expects estimates projects positioned strategy and similar expressions and are based on assumptions and assessments made in light of managements experience and perception of historical trends current conditions expected future developments and other factors believed to be appropriate forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements applicable risks and uncertainties include risks and uncertainties associated with the initiation timing progress and results of the companys research preclinical studies and clinical trials as well as risks and uncertainties identified under the heading risk factors included in galmeds most recent annual report on form f filed with the securities and exchange commission or the sec on march   and in other filings that galmed has made and may make with the sec in the future the forwardlooking statements contained in this press release are made as of the date of this press release and reflect galmeds current views with respect to future events and galmed does not undertake and specifically disclaims any obligation to update or revise any forwardlooking statements whether as a result of new information future events or otherwisegalmed pharmaceuticals ltd logo prnewsfotogalmed pharmaceuticals ltdmore to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesgalmedpharmaceuticalsannouncestheelectionofdrcarollbrosgartasanewmemberoftheboardofdirectorshtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextkristin beck transgender navy seal hero lets meet face to face and you tell me im not worthybusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredtrump’s big foxconn announcement will bring jobs — and robotsyahoo financeap exclusive boy scouts chief expected a fiery trump speechassociated pressamazon’s echo rivaled by xiaomi and facebook rptyahoo finance videodiscover it  out of  avg by k customersdiscover cardsponsoredamazon earnings — what you need to know in markets on thursdayyahoo financewhy everybody should be happy that flash is finally dyingyahoo financehighest ranking retired transgender officer slams new plan i think trump is ‘being influenced by pence’business insiderthe new reason why no studio will cast jim anymorekiwi reportsponsoredmccain slams trumps transgender military ban says its why major policy announcements should not be made via twitterbusiness insidertrump forges ahead to tax reformyahoo finance videomoney basics what is a hedge fundyahoo financebuy one give oneattsponsoredphil mickelson trashtalked jordan spieth at the open championship — and phil is going to have to eat his wordsbusiness insiderfacebook shares hit record high as mobile ad sales soarreutersprotests erupt nationwide following trumps transgender military ban announcementsergeant bill here we go again taxpayers shouldnt have to pay for a sex change for a military member and thats why this is happeningso they dont have to wowjoin the conversation   galmed pharmaceuticals announces the election of dr carol l brosgart as a new member of the board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 99 thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street galmed pharmaceuticals announces the election of dr carol l brosgart as a new member of the board of directors pr newswire jun    am edt tel aviv israel june   prnewswire  galmed pharmaceuticals ltd nasdaq glmd galmed or the company a clinicalstage biopharmaceutical company focused on the development of a oncedaily oral therapy for the treatment of nonalcoholic steatohepatitis or nash and other liver diseases announced today that on june   the company held an annual general meeting of shareholders the meeting at which the companys shareholders voted to elect dr carol l brosgart as a new class i director to serve as a member of the board of directors until the close of the annual general meeting to be held in  dr brosgart brings a vast array of clinical policy and corporate experience to galmed having held senior management positions with several leading pharmaceutical and life sciences companies dr brosgart as vice president clinical research at gilead sciences oversaw the nda eu and global approvals and launches of viread ™ for hiv and hepsera ™ for hepatitis b recently she served for eight years as a member of the board of directors of tobira therapeutics until it was acquired by allergan in november  she is also active in the public policy arena for aasld and idsahivma dr brosgart is a member of the executive committee of the forum for collaborative research fcr at the university of california berkeley and has served on both the steering committee of the fcrs liver forum which is a leader in the field of collaborative research focused on nash and the fcrs hbv forum focused on cure research for hepatitis b she has published widely in the field of chronic viral infections and liver disease and serves as a clinical professor of medicine biostatistics and epidemiology at the university of california san francisco ucsf allen baharaff galmeds president and chief executive officer stated dr brosgart has extensive clinical and drug development experience with direct relevance to both our clinical studies in nash the arrest study and hiv associated nafld and lipodystrophy the arrive study we believe her experience in launching successful new drugs and navigating commercial launches and corporate transactions will prove invaluable to galmed as we continue our drug development in chronic liver disease if you liked this article you might like shark bites stock picking makes a comeback market ends the week with some profittaking rev shark sep    am edt i am one of the underinvested bulls right now its challenging to put cash to work but ill keep digging rev shark sep    am edt these biotech names are on my radar but im expecting that things will slow into the fed news rev shark sep    am edt why galmed pharmaceuticals glmd stock is surging today shares of galmed pharmaceuticals glmd soared tuesday after the company announced the fda had given fast track designation to its drug candidate aramchol andrew meola sep    pm edt trending tesla headlines this lineup of  amazing new cars for  ftc seen as set to block rite aid deal apples iphone  is coming and it could be in your hands very soon honda accord through the years  reasons the  model is a really big deal jim cramer reveals why hes pleased with advanced micro devices and boeings earnings advertising partners 99 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers page not found  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use 99 thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories 99 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers alios biopharma names carol l brosgart m d as chief medical officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       alios biopharma names carol l brosgart md as chief medical officer tweet   am click here for details carol l brosgart md chief medical officer alios biopharma inc south san francisco camarketwire  february    highlighted links httpwwwaliosbiopharmacom alios biopharma inc today announced the appointment of carol l brosgart md as chief medical officer in this position dr brosgart will be responsible for leading the companys clinical drug development programs and will report to lawrence m blatt phd founder and chief executive officer of alios biopharma inc i have known carol for several years and we are extremely excited that someone of her caliber and expertise is joining the alios team at this critical time in our corporate development said dr blatt with her important experience leading the clinical development of successful antiviral programs at gilead along with her long track record of clinical focus on virology carol will play a critical role in advancing the alios lead development candidates into phase i clinical trials in addition carols deep understanding of clinical trials design in the area of virology should facilitate rapid development of our lead programs in various antiviral clinical indications i am very pleased to join alios biopharma at such an exciting stage of its development said dr brosgart alios has a promising pipeline of antiviral products and is well positioned to achieve its goal of bringing innovative therapeutics to patients dr brosgart joins alios from childrens hospital  research center in oakland california where she served as senior vice president and chief medical officer previously she gained more than a decade of pharmaceutical industry experience at gilead sciences inc where she held a number of senior management roles most recently as vice president public health and policy and earlier as vice president clinical research and vice president medical affairs and global medical director hepatitis during her tenure leading clinical research at gilead two antiviral clinical drug development programs  viread® for the treatment of hiv and hepsera® for the treatment of chronic hepatitis b  were approved by the fda and regulatory agencies worldwide prior to gilead dr brosgart worked for more than  years in clinical care research and teaching at several bay area medical centers thirty years ago she was among the first physicians in the country to recognize and treat patients with hivaids among her many accomplishments dr brosgart directed nih collaborative research trials as a member of the leadership of the community programs for clinical research on aids and prior to joining gilead she contributed to the development of all of the antiretrovirals for hiv and the agents for the prophylaxis and treatment of opportunistic complications of hiv dr brosgart received her bs in community medicine from the university of california berkeley ucb and her md from the university of california san francisco ucsf she completed postgraduate training in pediatrics at ucsf and completed an additional residency in preventive medicine offered by a joint program of the california state department of public health and ucb school of public health she has published extensively in the areas of infectious diseases focusing on antiviral therapy for cmv hiv hbv and related public health policy about alios biopharma alios biopharma inc an emerging biotechnology company headquartered in south san francisco california is developing novel medicines to treat viral diseases by activating pathways in the innate immune system alios is also developing nucleoside and nucleotide based therapeutics for the treatment of viral diseases including hepatitis c for more information wwwaliosbiopharmacom contacts debra bannister mediacommunications consultant 9 alios biopharma bruce bryan mba corporatesenior director of operations and project management email contact read at biospacecom related news alios biopharma issued broad us patent for glycoengineered interferons patheon ptito announces appointment of james c mullen as chief executive officer alios biopharma closes  million series a financing delenex therapeutics appoints eric de la fortelle as ceo and jakob schlapbach as cfo biotech industry veteran k peter hirth joins alios biopharma board of directors genocea biosciences names new ceo alios biopharma jobs raises  million hedge fund wants actelion ltd aliofpk ceo to quit bayer healthcare pharmaceuticals bayaf streamlines healthcare operations scripps president richard lerner to step down be replaced by berkeley chemist sources say please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • alios biopharma   • biotechpharma  personnel • biotechpharma  personnel world                 alios biopharma names carol l brosgart m d as chief medical officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       alios biopharma names carol l brosgart md as chief medical officer tweet   am click here for details carol l brosgart md chief medical officer alios biopharma inc south san francisco camarketwire  february    highlighted links httpwwwaliosbiopharmacom alios biopharma inc today announced the appointment of carol l brosgart md as chief medical officer in this position dr brosgart will be responsible for leading the companys clinical drug development programs and will report to lawrence m blatt phd founder and chief executive officer of alios biopharma inc i have known carol for several years and we are extremely excited that someone of her caliber and expertise is joining the alios team at this critical time in our corporate development said dr blatt with her important experience leading the clinical development of successful antiviral programs at gilead along with her long track record of clinical focus on virology carol will play a critical role in advancing the alios lead development candidates into phase i clinical trials in addition carols deep understanding of clinical trials design in the area of virology should facilitate rapid development of our lead programs in various antiviral clinical indications i am very pleased to join alios biopharma at such an exciting stage of its development said dr brosgart alios has a promising pipeline of antiviral products and is well positioned to achieve its goal of bringing innovative therapeutics to patients dr brosgart joins alios from childrens hospital  research center in oakland california where she served as senior vice president and chief medical officer previously she gained more than a decade of pharmaceutical industry experience at gilead sciences inc where she held a number of senior management roles most recently as vice president public health and policy and earlier as vice president clinical research and vice president medical affairs and global medical director hepatitis during her tenure leading clinical research at gilead two antiviral clinical drug development programs  viread® for the treatment of hiv and hepsera® for the treatment of chronic hepatitis b  were approved by the fda and regulatory agencies worldwide prior to gilead dr brosgart worked for more than  years in clinical care research and teaching at several bay area medical centers thirty years ago she was among the first physicians in the country to recognize and treat patients with hivaids among her many accomplishments dr brosgart directed nih collaborative research trials as a member of the leadership of the community programs for clinical research on aids and prior to joining gilead she contributed to the development of all of the antiretrovirals for hiv and the agents for the prophylaxis and treatment of opportunistic complications of hiv dr brosgart received her bs in community medicine from the university of california berkeley ucb and her md from the university of california san francisco ucsf she completed postgraduate training in pediatrics at ucsf and completed an additional residency in preventive medicine offered by a joint program of the california state department of public health and ucb school of public health she has published extensively in the areas of infectious diseases focusing on antiviral therapy for cmv hiv hbv and related public health policy about alios biopharma alios biopharma inc an emerging biotechnology company headquartered in south san francisco california is developing novel medicines to treat viral diseases by activating pathways in the innate immune system alios is also developing nucleoside and nucleotide based therapeutics for the treatment of viral diseases including hepatitis c for more information wwwaliosbiopharmacom contacts debra bannister mediacommunications consultant 9 alios biopharma bruce bryan mba corporatesenior director of operations and project management email contact read at biospacecom related news alios biopharma issued broad us patent for glycoengineered interferons patheon ptito announces appointment of james c mullen as chief executive officer alios biopharma closes  million series a financing delenex therapeutics appoints eric de la fortelle as ceo and jakob schlapbach as cfo biotech industry veteran k peter hirth joins alios biopharma board of directors genocea biosciences names new ceo alios biopharma jobs raises  million hedge fund wants actelion ltd aliofpk ceo to quit bayer healthcare pharmaceuticals bayaf streamlines healthcare operations scripps president richard lerner to step down be replaced by berkeley chemist sources say please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • alios biopharma   • biotechpharma  personnel • biotechpharma  personnel world                 galmed pharmaceuticals announces the election of dr carol l brosgart as a new member of the board of directors  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings press release june    am edt galmed pharmaceuticals announces the election of dr carol l brosgart as a new member of the board of directors tel aviv israel june   prnewswire  galmed pharmaceuticals ltd quoteszigman9composite glmd  galmed or the company a clinicalstage biopharmaceutical company focused on the development of a oncedaily oral therapy for the treatment of nonalcoholic steatohepatitis or nash and other liver diseases announced today that on june   the company held an annual general meeting of shareholders the meeting at which the companys shareholders voted to elect dr carol l brosgart as a new class i director to serve as a member of the board of directors until the close of the annual general meeting to be held in  dr brosgart brings a vast array of clinical policy and corporate experience to galmed having held senior management positions with several leading pharmaceutical and life sciences companies dr brosgart as vice president clinical research at gilead sciences oversaw the nda eu and global approvals and launches of viread ™ for hiv and hepsera ™ for hepatitis b recently she served for eight years as a member of the board of directors of tobira therapeutics until it was acquired by allergan in november  she is also active in the public policy arena for aasld and idsahivma dr brosgart is a member of the executive committee of the forum for collaborative research fcr at the university of california berkeley and has served on both the steering committee of the fcrs liver forum which is a leader in the field of collaborative research focused on nash and the fcrs hbv forum focused on cure research for hepatitis b she has published widely in the field of chronic viral infections and liver disease and serves as a clinical professor of medicine biostatistics and epidemiology at the university of california san francisco ucsf allen baharaff galmeds president and chief executive officer stated dr brosgart has extensive clinical and drug development experience with direct relevance to both our clinical studies in nash the arrest study and hiv associated nafld and lipodystrophy the arrive study we believe her experience in launching successful new drugs and navigating commercial launches and corporate transactions will prove invaluable to galmed as we continue our drug development in chronic liver disease dr brosgart stated i am pleased to join the board of directors of galmed a leading company in clinical research in nash and fibrosis nash a chronic progressive liver disease in the spectrum of nonalcoholic fatty liver disease has rapidly become a leading cause for endstage liver disease hepatocellular carcinoma and liver transplantation both in the united states and globally nash is a complex disease that will likely require therapy that addresses the underlying metabolic abnormalities in addition to inflammation and fibrosis for the full results of the meeting please refer to the companys form k filed with the securities and exchange commission on june   about aramchol™ and nonalcoholic steatohepatitis nash aramchol ™ arachidyl amido cholanoic acid is a novel fatty acid bile acid conjugate inducing beneficial modulation of intrahepatic lipid metabolism aramchol ™ s ability to modulate hepatic lipid metabolism was discovered and validated in animal models demonstrating down regulation of the three key pathologies of nash steatosis inflammation and fibrosis the effect of aramchol ™ on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells aramchol ™ has been granted by the fda fast track designation status for the treatment of nash nash is an emerging world crisis impacting  to  of the us population and  to  globally it is the fastest growing cause of liver cancer and liver transplant in the us due to the rise in obesity nash is the progressive form of nonalcoholic fatty liver disease that can lead to cardiovascular disease cirrhosis and liverrelated mortality about galmed pharmaceuticals ltd galmed is a clinicalstage biopharmaceutical company focused on the development of aramchol ™  a first in class novel oncedaily oral therapy for the treatment of nash for variable populations as well as other liver associated disorders galmed is currently conducting the arrest study a multicenter randomized double blind placebocontrolled phase iib clinical study designed to evaluate the efficacy and safety of aramchol ™ in subjects with nash who are overweight or obese and who are prediabetic or typeiidiabetic galmed also sponsors the arrive study a proofofconcept phase iia clinical trial designed to evaluate the safety and efficacy of aramchol in up to  patients with hivassociated nafld and lipodystrophy the arrive study is an investigatorinitiated trial conducted at the university of california san diego by professor rohit loomba more information about the arrest study and the arrive study may be found on clinicaltrialsgov identifiers nct9 and nct9 respectively forwardlooking statements this press release may include forwardlooking statements forwardlooking statements may include but are not limited to statements relating to galmeds objectives plans and strategies as well as statements other than historical facts that address activities events or developments that galmed intends expects projects believes or anticipates will or may occur in the future these statements are often characterized by terminology such as believes hopes may anticipates should intends plans will expects estimates projects positioned strategy and similar expressions and are based on assumptions and assessments made in light of managements experience and perception of historical trends current conditions expected future developments and other factors believed to be appropriate forwardlooking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements applicable risks and uncertainties include risks and uncertainties associated with the initiation timing progress and results of the companys research preclinical studies and clinical trials as well as risks and uncertainties identified under the heading risk factors included in galmeds most recent annual report on form f filed with the securities and exchange commission or the sec on march   and in other filings that galmed has made and may make with the sec in the future the forwardlooking statements contained in this press release are made as of the date of this press release and reflect galmeds current views with respect to future events and galmed does not undertake and specifically disclaims any obligation to update or revise any forwardlooking statements whether as a result of new information future events or otherwise   to view the original version on pr newswire visit httpwwwprnewswirecomnewsreleasesgalmedpharmaceuticalsannouncestheelectionofdrcarollbrosgartasanewmemberoftheboardofdirectorshtml source galmed pharmaceuticals ltd copyright c  pr newswire all rights reserved quoteszigman9composite add to watchlist glmd galmed pharmaceuticals ltd us  us nasdaq     volume  july   9p pe rationa dividend yieldna market cap9 million rev per employee9 most popular  cocacola to replace coke zero in us  if you can buy only one stock or etf make it this one  market snapshot stock market ends at record on robust earnings as fed issues policy update  americans in this field have the highest rate of divorce by age   lego boost the ultimate kid review find a broker partner center » featured stories seeing america again through new eyes how to dig yourself out of debt move over tesla karma unveils its hybrid sports car the salary you need to afford a home in these  cities why opec will never cut production again log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest adaily mail revenue up warns on some markets aweir profit jumps on strong oil and gas showing asmith  nephew profit rises on track for targets aspains unemployment rate drops to  avolkswagen profit up lifts sales guidance athomas cook loss halves backs fullyear guidance alloyds profit narrows on £ bln compensation bill aairbus profit down  on lower plane deliveries atate  lyle profit ahead backs fullyear guidance 9aoil majors sustain profits despite crudes slide aastrazenecas mystic cancer drug trial fails aastrazenecas mystic lung cancer trial fails to meet endpoint aastrazeneca tumbles  after decline in quarterly revenue adeutsche bank shares falls  after earnings report aanglo american up  after dividend reinstatement agermanys dax opens  lower at  afrances cac  opens  lower at  auks ftse  opens  lower at  astoxx europe  opens  lower at  anestlé sales growth lags profit rises on tax bump loading more headlines dow quoteszigman9realtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml  99 99 lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext9 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft carol brosgart  netfind content results aol search skip over navigation search the web web web content your search for carol brosgart returned no results search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network